Caxton Associates LLP Exelixis, Inc. Transaction History
Caxton Associates LLP
- $4.11 Billion
- Q3 2025
A detailed history of Caxton Associates LLP transactions in Exelixis, Inc. stock. As of the latest transaction made, Caxton Associates LLP holds 13,323 shares of EXEL stock, worth $554,902. This represents 0.01% of its overall portfolio holdings.
Number of Shares
13,323
Previous 24,560
45.75%
Holding current value
$554,902
Previous $1.08 Billion
99.95%
% of portfolio
0.01%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding EXEL
# of Institutions
697Shares Held
257MCall Options Held
1.5MPut Options Held
1.71M-
Black Rock Inc. New York, NY33.5MShares$1.4 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA26.1MShares$1.09 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA19.5MShares$812 Million3.48% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.5MShares$644 Million0.9% of portfolio
-
State Street Corp Boston, MA11.1MShares$463 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $13.4B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...